Catherine Bonuccelli
AstraZeneca
12
0
12
N/A
0
0
Research Impact
N/A
Research impact score
0
Total publications
0
Published trial results
0
Total citations
Drug Portfolio
+3 more interventions
Analytics
Trial Phases
Trial Status
Role Distribution
Activity Timeline
Clinical Trials (12)
Showing 10 of 12 trials
Research Network
Collaboration Network
Research Areas & Affiliations
Therapeutic Areas
Affiliations
Similar Key Opinion Leaders
Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.
Michael E Ruff, MD
Pharmaceutical Research & Consulting Inc
Shared therapeutic areas:
Worked with same sponsors:
Mitchell Golmand, MD
AstraZeneca
Shared therapeutic areas:
Worked with same sponsors:
Liza O'Dowd, MD
AstraZeneca
Shared therapeutic areas:
Worked with same sponsors:
Nikolaos Harokopos, MD
General hospital of Pyrgos, Peloponnese, Greece
Shared therapeutic areas:
Anastasios Palamidas, MD
Sotiria Pulmonary Hospital of Athens
Shared therapeutic areas:
Anna Gavriilidou, MD
Papageorgiou hospital of Thessaloniki, Greece
Shared therapeutic areas:
Ali MA Ismail, lecturer
Cairo University
Shared therapeutic areas:
Areti Xifteri-Nikolinati, MD
Messini, Greece
Shared therapeutic areas:
Maria Katertzi, MD
Private office, Moudania, Thessaloniki, Greece
Shared therapeutic areas:
Evangelia Tsikrika, MD
General hospital of Veroia, Greece
Shared therapeutic areas:
Publications (0)
No publications found for this investigator.
Clinical Trials (12)
Showing 12 of 12 trials
Efficacy of Symbicort pMDI Administered Once Daily in Children and Adolescents During 12 Weeks - SPROUT
Efficacy of Symbicort Versus Its Monocomponents - SPRUCE 80/4.5
Efficacy of Symbicort Versus Its Monocomponents - SPRUCE 160/4.5
Efficacy of Symbicort pMDI Administered Once Daily in Adolescents and Adults During 12 Weeks - STEM
Relative Bronchodilating Effects of Formoterol When Administered Via Symbicort Pressurized Metered-dose Inhaler (pMDI) or Oxis Turbuhaler
All 12 trials loaded